Cooperative Agreement UL1TR000001

This federal Cooperative Agreement award of $17,134,164 from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, will establish the Consortium for Translational and Precision Health (CTPH) led by Baylor College of Medicine and the University of Houston. The CTPH will serve as a hub to advance clinical translational science, precision health, and health equity through new technologies, research methods, community engagement, and workforce development. Key objectives...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $290,881 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis). The grant, titled "Indiana Stimulating Access to Research in Residency (I-STARR)", aims to train up to 12 primary care resident-physicians in research methods focused on understanding and reducing health disparities in...

The National Human Genome Research Institute (NHGRI) awarded a $658,448 Cooperative Agreement to Trustees of Indiana University (Indiana University Indianapolis) to implement a Genomics-Enabled Learning Health System (GLHS) across Indiana. The goal of this 5-year project is to identify strategies for improving the integration of genomic testing, reporting, and use into clinical workflows. The project will leverage past accomplishments in genetic testing infrastructure and expertise to conduct...

This federal Project Grant award for $974,000.00 was provided by the National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350 - National Center for Advancing Translational Sciences. The grant funds the CTSA K12 Program at the University of Texas Health Science Center at Houston (UTHealth), which aims to develop a well-trained and adaptable clinical and translational science workforce capable of rapid clinical trial design and deployment. The program includes...

This $587,249.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to investigate the role of the CDK8 kinase in regulating cardiac transcription and its potential as a therapeutic target for pathological cardiac hypertrophy and heart failure. The key objectives of the project are to: 1) determine the therapeutic potential of small-molecule CDK8 inhibitors, 2)...

This federal Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides funding of $244,000.00 to the Oregon Health & Science University (OHSU) to investigate the benefits of intensive induction chemotherapy followed by immediate hematopoietic cell transplantation (HCT) for patients with intermediate and high-risk acute myeloid leukemia (AML). The project aims to determine if this...

This federal Project Grant award, totaling $596,401, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, effective May 1, 2025, supports research to investigate the role of a novel long non-coding RNA called MCRL1 in regulating human cardiac and hematopoietic differentiation. The research, conducted by the Trustees of Indiana University (Indiana University Indianapolis), aims to...

This $17,123,289 federal Cooperative Agreement award from the National Center for Advancing Translational Sciences (CFDA 93.350) supports the "Center for Clinical and Translational Sciences" (CCTS) at the University of Texas Health Science Center at Houston (UTHealth) and its partner institutions across Texas. The CCTS program aims to enhance translational science and accelerate the delivery of new treatments to diverse populations through six strategic goals, including expanding...

The University of Texas Southwestern Medical Center was awarded a $2,340,322 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on August 15, 2024. The project, titled "Avoiding Cardiovascular Complications in Liver Transplantation Through Novel Studies (ACCT NOW) in Hypertension," aims to conduct a 2-year prospective, multicenter cohort study of 1,268 liver transplant recipients. The study will measure 7-day home blood...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,428,701 to the University of Missouri at Kansas City (UMKC) to conduct a prospective, multi-site study of 1,000 pregnant individuals with cardiovascular disease. The study aims to identify patient characteristics and structural care factors associated with adverse pregnancy outcomes, maternal cardiovascular events, and...